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Abstract
Background The Royal College of Physicians (RCP) and Thyroid Eye Disease Amsterdam Declaration Implementation
Group (TEAMeD-5) have the common goal of improving access to high quality care for thyroid eye disease (TED). The
TEAMeD-5 programme recommends all patients with moderate-to-severe TED should have access to multidisciplinary
clinics (MDT) with combined Ophthalmology and Endocrinology expertise.
Methods The British Oculoplastic Surgery Society represents oculoplastic surgeons who usually lead TED care in the UK.
A two-stage survey of the membership was conducted to ascertain current practice of existing resources.
Results Seventy percent (45/65) of respondents in Survey 1 were aware of current RCP guidance, but only 49% (22/45)
rated it as a good means of improving access to comprehensive TED service. Sixty percent (39/65) of respondents are
working in a multidisciplinary TED clinic with co-location of ophthalmologists and endocrinologists. Care for TED appears
not to be provided in a multidisciplinary context in up to 31% (20/65). Thirty five (54%) of the respondents rated their
relationship with endocrinology colleagues as good. Best practice guidelines recommend routine quality of life assessments
but only 6/28 (21%) of respondents use this modality in current practice. Six percent (4/65) of areas appear not to be using
intravenous steroids. In many areas (25%, 16/65), second-line immunosuppression is provided in a different trust and in 8%
(5/65), it appears not to be used at all.
Conclusion This survey is a ‘snapshot’ of current TED management in the UK and findings suggest scope for improvement.
We recommend a framework for more robust collaboration across specialties and propose standards endorsed by multi-
disciplinary stakeholder societies.
Introduction
Multidisciplinary clinics for complex disease have become
the gold standard of care in recent years. This is based on
the premise that care given by a group of clinical profes-
sionals is more comprehensive than that provided by a
single individual, and that specialist skills and knowledge
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are used more appropriately avoiding duplication and gaps
in care.
Previous studies have reported age-adjusted annual
incidence rates of 42/million for thyroid eye disease (TED)
of all severity (10/million for moderate-to-severe disease)
[1]. The most accurate estimate of prevalence of all cases of
TED in Europe is 0.1% [2]. The burden of disease can have
significant impact on physical and psychosocial wellbeing,
may be disfiguring and occasionally sight threatening [3, 4].
There is now robust evidence to show the severity of resi-
dual disease can be substantially decreased by timely spe-
cialist intervention [5]. The Amsterdam Declaration [6] led
by the European Group on Graves’ Orbitopathy
(EUGOGO), and signed by over 80 professional and
patient-led organisations in 2009, aimed to improve out-
comes for patients with TED. Presentation of TED [7] and
subsequent studies show multidisciplinary team (MDT)
clinics improve access to care. Its recommendations include
support for existing centres of excellence in management of
this condition, the creation of new centres of excellence in
localities where they are lacking and to establish audit and
monitoring mechanisms of quality assurance of provision of
care to people with TED. The 2008 consensus statement
from EUGOGO [8] and the 2016 European Thyroid
Association Guidelines on Graves’ Orbitopathy [9] recom-
mended joint multidisciplinary care between specialties
(ophthalmology and endocrinology) for all cases of mod-
erate or severe TED. Several studies from the UK and other
European countries have highlighted delays in the diagnosis
of TED and referral to specialist centres and that many
patients with moderate or severe disease were not managed
in appropriately skilled specialist centres [7, 10–13].
In the UK, Thyroid Eye Disease Amsterdam Declaration
Implementation Group (TEAMeD: http://www.btf-thyroid.
org/projects/teamed) was formed to implement the
Amsterdam Declaration objectives and improve outcomes
for patients with TED [7]. TEAMeD have subsequently
conducted epidemiological surveys that have shown sig-
nificant regional variation within the UK in care pathways
and availability of specialist surgery [10, 11, 14]. Often
significant delays have resulted in the active disease phase
being missed, along with the window for disease modifying
intervention [11]. In 2015, the Royal College of Physicians
(RCP) (endorsed by Royal College of Ophthalmologists,
BOPPS, British Thyroid Association and Society for
Endocrinology) issued updated guidelines on management
of patients with Graves’ orbitopathy: initial assessment,
management outside specialised centres and criteria for
referral to specialist care [7] with additional guidance
published subsequently by EUGOGO [9].
To implement these recommendations and raise aware-
ness of prevention measures and early referral of TED
amongst the endocrine community, the TEAMeD-5
programme was launched within the UK in 2017. Given
that more than 80% of TED presents in patients with a
known diagnosis of Graves’ disease, TEAMeD-5 recom-
mends [15] the following:
(1) accurate diagnosis of Graves’ disease to identify
patients at risk of TED (e.g. TSH receptor antibody
testing);
(2) screening of all patients with Graves’ disease for early
symptoms and signs of TED;
(3) alerting individuals with Graves’ disease to the early
symptoms of TED using an awareness card;
(4) optimising measures to prevent and reduce the
severity of TED by smoking reduction, early induc-
tion and maintenance of euthyroidism and avoidance
of radioiodine in active TED;
(5) prompt referral of individuals with moderate or severe
TED or TED affecting quality of life directly to a
regional specialist multidisciplinary clinic with appro-
priate experience and expertise [16].
Prior to this initiative launch, the British Oculoplastic
Surgery Society (BOPSS) liaised closely with TEAMeD
and a two-part survey was designed to assess the readiness
of ophthalmic services across the UK to comply with the
recommendations.
Methods
This was the first full membership survey approved by the
BOPSS Executive Committee and comprised of two sec-
tions. Survey 1 included questions (Supplementary Fig. 1)
on the regional location of respondent, their awareness of
the 2015 RCP guidance and perception of its utility, their
relationship with their local endocrinology department and
whether there were any screening arrangements for TED
agreed locally. Further questions included the availability of
a geographically accessible multidisciplinary combined
thyroid eye clinic with Ophthalmologists and Endocrinol-
ogists, staffing provisions, treatment modalities available
within their hospital trust and whether they used a particular
treatment.
All respondents of Survey 1 were then invited to com-
plete Survey 2, which included more detailed questions
about their service configuration (Supplementary Fig. 1).
The survey went ‘live’ on the BOPSS website in December
2016 with an email invitation to the full BOPSS member-
ship consisting of post-CCT (Certificate of Completion of
Training) ophthalmic surgeons with subspecialty expertise
in oculoplastics. The preliminary findings of the survey
were presented at the BOPSS London 2017 Annual Meet-
ing by the authors to discuss various aspects of
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multidisciplinary working in collaboration with speakers
across different regions of the UK showcasing their local
services. The session terminated with an invitation to all full
members who had not previously participated to complete
the survey and a further email invitation was re-sent fol-
lowing the meeting. The survey closed in August 2017.
‘Specialist multidisciplinary (MDT) services’ for TED
management clinic was defined as co-location of an endo-
crinologist with an ophthalmologist within the same clinic.
An online discussion of a group of full members was set
up under the aegis of BOPSS with representatives from
across the UK to discuss recommendations and regular
progress reporting by author VL at the Executive Com-
mittee meetings. Data were presented at the full members’
annual general meeting in 2018 for discussion and feed-
back. Draft versions of this paper were circulated to
representatives of all stakeholder societies within TEAMeD
and comments incorporated into subsequent versions
Results
The original survey was first sent out to all members (n=
150) in December 2016 with a final survey reminder sent
out to all BOPSS members (n= 158) in August 2017.
Survey 1: general service configuration
There were 65 respondents to Survey 1 (41% of the BOPSS
full membership) and 28 respondents (43%) to Survey 2.
Individuals across all regions in the UK participated for
Survey 1 (Fig. 1a). Forty-five (69%) respondents were
aware of the 2015 guidance. Of these, 22/45 (49%) con-
sidered that these as a good, 21/45 (47%) as an average and
2/45 (4%) as a poor guide to improving access of patients to
comprehensive thyroid eye services.
Across the UK, 20/65 (29%) respondents do not use
specialist multidisciplinary services for TED management,
with 39/65 (60%) working in a dedicated multidisciplinary
(MDT) thyroid eye clinic with co-location of endocrinology
and ophthalmology and 6/65 (9%) referring patients to
another trust within a dedicated thyroid eye clinic setup
(Fig. 2). Twenty respondents do not have an MDT thyroid
eye clinic, respondents who do not use multidisciplinary
services were located in seven out of nine geographical
regions of the UK (Fig. 2).
Thirty-five respondents (54%) rated their relationship
with their local endocrinology department as good, 22/65
(34%) average and 4/65 (6%) poor and 4 (3%) did not
comment. Sixty-one (94%) respondents used intravenous
methyl prednisolone (IVMP) as part of TED management in
their own trust. Two (3%) respondents did not use IVMP
and another two (3%) referred patients to another trust for
IVMP treatment. Forty four (68%) offered second-line
immunosuppression (when first-line therapy with intrave-
nous steroids has failed/ ceased working) within their own
trust. Forty (62%) offered orbital decompression within their
own trust, with over a third referred to another trust, and 3%
(2/65) responding that they did not offer orbital decom-
pression to their TED patients (Supplementary Fig. 2). Sixty
Fig. 1 Number of respondents from each region of the UK for a
Survey 1 and b Survey 2 for whether patients with TED are managed
within a multidisciplinary setting at minimum monthly intervals. For
Survey 2, there were no respondents from Scotland or Wales. ‘Spe-
cialist multidisciplinary (MDT) services’ for TED management clinic
was defined as co-location of an endocrinologist with an ophthal-
mologist within the same clinic. A “dedicated thyroid eye clinic” was
defined as a specialised ophthalmology clinic for thyroid eye patients
only (does not include the presence of an endocrinologist)
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four (97%) offered oculoplastic and fifty seven (88%)
strabismus surgery to TED patients within their own trust.
Survey 2: detailed service configuration
Twenty-eight (18% of the membership) respondents com-
pleted Survey 2 (with no respondents from Wales or Scot-
land). Seventeen out of twenty eight (61%) of the
respondents stated that they treated patients within a MDT
thyroid eye clinic with an endocrinologist present (Fig. 1b).
Two-thirds (68%) included orthoptic support, but only
approximately a third (36%) included other health profes-
sionals (including immunosuppression specialists). Four-
teen out of twenty eight (50%) responded that their local
endocrine service did not routinely screen for TED. Of
those who affirmed that screening did take place, two
respondents stated that they did not know how their local
endocrinologists screened for TED and the remainder
reported that a variety of screening tools including Van-
couver orbitopathy score and NOSPECS were used. Fifteen
(54%) reported that smoking cessation services were
available within their own trust or locally, and the remain-
der said they did not know about local provision. Twenty-
four (85%) and 22 (79%) individuals reported that thyr-
oidectomy and radioiodine were carried out within their
own trust.
Both MRI and CT scans (27/28) were widely used orbital
imaging modalities. Twenty-three out of twenty-eight
(82%) respondents stated they routinely gave their
patients written information regarding TED, but only 6/28
(22%) routinely collected patient reported outcomes and
quality of life measurements. This more detailed survey
Fig. 2 Responses based on geographic location from Survey 1 on type of management provided within own clinical unit or referral to another
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confirmed a large variation of treatment modalities and
experience of using intravenous steroids, oral prednisone,
periocular steroids and second-line immunosuppression
(Fig. 3). Figure 3 reflects the number of patients treated/
referred per year by each respondent, according to treatment
modality. Twenty seven (96%) used intravenous steroids of
which 16 were administered by the eye department (the
remainder by other physicians). Twenty five (89%)
(Fig. 3b) used oral prednisolone as part of TED treatment;
periocular steroids were used by ten (36%) respondents
(Fig. 3c); 26 (93%) offered second-line immunosuppression
within their own unit (Fig. 3d) and 26 (93%) used orbital
radiotherapy—18 within own trust and eight referral to
another unit and not used by two respondents as part of
TED treatment (Fig. 3e).
The text of both Surveys 1 and 2 are available in Sup-
plementary Fig. 1.
The referral pattern and local availability of TED treat-
ments are detailed in Supplementary Fig. 2.
Discussion
The concept of combined multidisciplinary clinics and
networks has now been well established in many dis-
ciplines, most notably in oncology where it works best to
harness all available expertise to optimise patient
management and outcomes. It has also shown that it
improves the time to diagnosis and treatment in TED [16].
We recognise that to formulate recommendations, there has
to be a process of consensus and its impact would be greater
if embraced by multiple professional organisations, espe-
cially when the topic is such that it transcends more than
one specialty.
This nationwide survey of ophthalmologists with an
interest in TED, being voluntary, represents a valuable
‘snapshot' of provision rather than a complete inventory of
TED care in the UK. The study was deliberately designed as
a two stage with a short Survey 1 to encourage participation
with more brief and general questions and Survey 2 to elicit
more information from those presumably already running
TED specialist clinics. With a 41% response to Survey 1
rate if we assume that the responders are the ‘enthusiasts',
then the data suggest that care for TED is not provided in a
multidisciplinary context with simultaneous endocrinology
and ophthalmology input in up to 40% of ophthalmology
clinics and the presence of geographical clusters leading to
uneven access to healthcare.
Whilst there is undoubtedly a desire for many endocri-
nology specialists to work within a multidisciplinary set-
ting, as demonstrated by a recent ‘snap shot’ survey of
endocrinologists [17], there is significant variation in clin-
ical practice. The reasons for lack of multidisciplinary ses-
sions are likely multifold. Firstly, many regions of the UK
Fig. 3 Responses to Survey 2 on numbers treated with a intravenous, b oral, c peri-ocular steroid treatment, d second-line immunosuppression and
e orbital radiotherapy
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may be spread across large geographical areas, particularly
when endocrinology and ophthalmology are not located on
the same site. Furthermore, provisions in the workforce may
limit the desire to take on additional clinics to support
multidisciplinary working. We speculate that much of this
perception of lack of support is due to lack of clear lines of
communication and may be hampered by the geographical
separation in some regions.
A few areas of the country appear not to be using
intravenous steroids and there is high usage of oral steroids
despite evidence for better efficacy and safety with intra-
venous steroids. However, given the way that the ques-
tionnaire was phrased the aim was to ascertain the different
treatment modalities in use in the UK rather than the choice
of first-line treatment. The recent BOSU national wide
surveillance on dysthyroid optic neuropathy found that 82%
of reporting units followed the EUGOGO protocol
for severe eye disease so this would suggest that many units
in the UK do follow the EUGOGO recommendations. The
significant use of oral steroids (89%), may reflect its use as
part of bridging treatment for second-line immunosuppres-
sion, where the ‘safe upper limit’ of intravenous
steroid dose of 8 g had been exceeded or as cover for
radioiodine treatment to mitigate the risk of orbitopathy
progression.
There is also relative high use of periocular steroids
(36%) despite lack of comparative efficacy and safety data
on this mode of administration compared with systemic
steroids. Again this may not be the respondent’s first-line
treatment of choice but utilised as adjunctive treatment to
intravenous steroids or where the first-line treatment of
choice is medically contraindicated, e.g. uncontrolled dia-
betes or in an already immunosuppressed patient or where
severe complications necessitated the termination of the
course of treatment [18, 19]. It is of note that even among
this group of possible ‘enthusiasts' second-line medical
therapy after steroids was not used by 32% of respondents
and in many areas was provided in a different trust. This is
particularly relevant in view of recent evidence of the
marginal benefits of adjunctive therapy combined with
steroids [20, 21]. Access to orbital decompression surgery
seems available in most parts of the UK, though frequently
in a different trust.
It is also apparent that the process of actively screening
for TED is suboptimal and not standardised and important
outcome data such as quality of life measures are not rou-
tinely collected. Multidisciplinary relationships between
ophthalmology and endocrinology teams could also be
improved in many centres. The importance of early diag-
nosis and treatment of TED for a better outcome is clearly
underlined by the Amsterdam declaration [2]. Results from
our study suggest that although progress is being made to
achieve these goals, there is still a substantial need for
further improvement. Optimal disease management of TED
can span across many different specialties (Supplementary
Fig. 3) and treatment timing is crucial to maximise efficacy
of the treatments in the acute phase, including thyroid hor-
monal control and control of the orbital inflammation [22].
Limitations of our BOPSS survey include that there may
be more than one respondent from the same unit completing
the survey. Despite multiple invitations and extensive
consultation at various national meetings over half of the
BOPSS full membership did not respond to the survey.
Moreover, respondents are also more likely to be a self-
selecting cohort with specialist interest in TED. It is there-
fore likely that they are overall better informed on TED, and
thus reality is likely under-represented with greater variation
and even less access to multidisciplinary working than
described in our study.
We believe two major approaches are required to achieve
fuller implementation and better uptake of the Amsterdam
Declaration. Firstly, the RCP guidance requires further
reinforcement and dissemination with adoption by all clin-
ical units, as part of adoption of the TEAMeD-5 pro-
gramme, and secondly, units treating TED should be able to
demonstrate compliance with auditable benchmarks.
While recognising the UK environment of finite resour-
ces within a national health service BOPSS drafted general
standards, which we believe should be achievable within
current resources (Table 1). This predominantly requires
improved communication between ophthalmologists and
endocrinologists and the establishment of locally agreed
operating procedures taking into account existing service
configurations.
After extensive consultation with BOPSS members
through discussion groups and presentations at executive
meetings, as well as the annual general meeting, the con-
sensus was that there should be evidence based national
benchmarks. However, implementation policies were felt by
the membership best decided by local stakeholders taking
into account variation in service configurations and varia-
tion across the country.
The proposed benchmarks (Table 1) received broad
acceptance across the BOPSS membership and the
TEAMeD stakeholder representatives. An initiative to
allocate a section of the members website to allow for
uploading of local practice guidelines to enable sharing of
best practice also received executive endorsement. In
addition, the BOPSS executive committee fully supported
the recent TEAMeD-5 proposal of identifying a lead
endocrinologist for each specific region to take ownership
and coordinate implementation of the programme. The role
should entail providing specialist training in diagnosis and
management of TED. Furthermore, it would involve
ensuring referrals are managed in a timely fashion, with a
proposed pathway to establish joint endo-ophthalmology
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services, and to include an audit programme, detailing
surgical activity and treatment outcomes. The standards set
should include ‘referral for assessment for TED’ and use of
a validated screening tool (e.g. the Vancouver orbitopathy
score or the DiaGO) [23, 24]. As demonstrated in our sur-
vey, there is significant lack of clarity how patients are
identified for referral.
We concur with TEAMeD-5 that all treating doctors
should alert patients about risk of TED [15]. Best practice
would be to use the TEAMeD TED early warning card [15]
to help identify patients with moderate/severe and sight-
threatening disease. It is well established that radioiodine
can exacerbate the onset and progression of TED [25],
therefore it is crucial that the two specialties agree to reduce
this risk particularly in smokers. All treating doctors should
offer smoking cessation advice and recommend referral to
smoking cessation services to all TED/Graves’ patients
who are smokers. A previous prospective multi-centre
study in the UK highlighted that not enough patients are
being provided with smoking cessation advice and infor-
mation on the impact of smoking on TED and control of
thyroid function [11]. Moreover, quality of life indicators
could routinely be incorporated into the standard con-
sultation template [26–28]. More clearly sign posted access
to psychological support would likely be beneficial.
The BOPSS executive committee has supported allo-
cating a dedicated website area so that members can
contribute their local standard operating procedures
(SOPs) to enable sharing of best practice. Locally agreed
SOP should include active screening for TED, indications
for steroid cover for Graves’ patients undergoing radio-
iodine treatment, and protocols for second-line immuno-
suppression. Local SOP should additionally incorporate
the use of immunosuppression orbital radiotherapy and
follow up protocol, as well as planning for rehabilitative
treatment. In view of many patient related adverse events
related to clinical administration, an SOP should be
developed to prevent patients with active thyroid orbito-
pathy from being lost to follow up and to be seen at
suitable intervals. Examples of best practice would
include a secure GDPR compliant TED patient database
and a ‘fail-safe officer'/multidisciplinary coordinator. This
is in line with the RCP recommendations as TED is a
condition with increased risk [29]. We recommend all
units treating TED should have an agreed protocol with
referring endocrinologists as to the thyroid treatment and
monitoring with clear documentation of communication
and treatment with best practice having a specialist joint
thyroid eye clinic with an endocrinologist and ophthal-
mologist in the same clinic.
Table 1 Proposed standards of care for multidisciplinary working between ophthalmologists and endocrinologists
To be agreed with referring endocrinologists
Essential Desirable
SOP for screening and referral Validated screening tool with audit of outcomes
Increased awareness of thyroid eye disease among all Graves’ disease patients TEAMeD thyroid eye disease early warning card
Smoking cessation Sign post and refer to smoking cessation services
Initiation of dry eye treatment as necessary in endocrine clinic Locally agreed treatment protocol
Clear guidelines regarding suitability for radioiodine treatment Local SOP for thyroid eye clinic referral
Clear routes of Communication MDT clinic
Eye clinic standard operating procedures (SOP)
Measures to avoid loss of follow up of patients with active orbitopathy Fail-safe officer
GDPR compliant patient database
Comprehensive clinic assessment Dedicated clinic protocol, regular QOL assessment and
clinical photographs
Orthoptic assessment for all patients with diplopia at baseline and at regular
intervals to monitor progression/ treatment effect
Local SOP
Recommendations include Hess and BSV assessments
Local agreed SOP for use of orbital imaging MDT radiology meeting
Written patient information Standard package of information leaflets covering all
aspects of thyroid eye disease
SOP for immunosuppression (first and second line) Locally agreed treatment and referral protocol
SOP for orbital radiotherapy (if used) Locally agreed treatment and referral protocol
SOP for sight-threatening disease Locally agreed treatment and referral protocol
SOP for rehabilitation treatment Locally agreed treatment and referral protocol
SOP standard operating procedure
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Within NHS trusts, audit should include numbers of
patients treated in each of the above categories and also the
most important metric—time from onset of symptoms of
eye disease to first treatment. It would not be controversial
to recommend that treatment for acute visual loss should be
initiated urgently.
To summarise, Table 1 outlines the recommended stan-
dards for multidisciplinary working between ophthalmolo-
gists and endocrinologists. Table 2 summarises the
combined quality standards for management of TED. In
conclusion, our data suggest that management of TED
across the UK is varied, with clinical practice not reflecting
national and regional guidelines. Evolution of local policies
and multidisciplinary teams are critical to address this
deficiency under the auspices of the TEAMeD-5 (Supple-
mentary Figs. 4) initiative. Hopefully a devolved approach
through identifying lead endocrinologists in each region to
take ownership and coordinate implementation of the
TEAMeD-5 programme will allow a structured training
program to fellow clinicians to ensure that an appropriately
configured and expert multidisciplinary service for mana-
ging moderate-to-severe cases of TED is present in all
regions.
Summary
What was known before
● The TEAMeD-5 programme recommends all patients
with moderate-to-severe TED should have access to
multidisciplinary clinics with combined Ophthalmology
and Endocrinology expertise
Table 2 Proposed audit criteria
for review of services managing
thyroid eye disease
(1) Efficacy Consideration of oral selenium supplements (91.3 mcg elemental selenium bd for
6 months) for patients with mild, active TED.
Smoking cessation advice for patients who are smokers (Target 80%).
Prompt correction of dysthyroidism and maintenance of euthyroidism.
Where systemic steroid treatment is indicated, use of intravenous pulses of
methylpred-nisolone in preference to oral steroids.
Availability of urgent treatment for sight-threatening orbitopathy, including surgical
decompression for patients who fail to respond to high dose intravenous steroids.
Availability of orbital irradiation.
Availability of rehabilitative surgery for patients with inactive or minimally active
disease who are significantly impaired, socially or psychologically as a result
of TED.
(2) Safety Appropriate selection of patients with TED who are being considered for
radioiodine for suitability of steroid cover.
Safe use of immunosuppressive treatments (exclusion of those for whom there are
contraindications, assessment and monitoring of risks of serious adverse effects.
Timely assessment of response to high dose intravenous steroids and withdrawal of
steroid treatment in favour of other therapies for those with inadequate response.
(3) Patient-centred
care
Availability of good quality information about TED, its usual course, likely
outcomes and potential treatments, complemented by high quality written
information and access to patient-led organisations.
Formulation of personalized management plans following multidisciplinary
discussion.
Good communication between the clinical team and the patient.
Patient engagement with the decision process about management of TED.
Use of validated tools to assess the impact of TED on their quality of life, like the
GO-QOL.
(4) Timely Patients with sight-threatening TED (dysthyroid optic neuropathy resulting in
significant reduction in visual acuity, corneal breakdown with impending or
established infection, globe subluxation) should be treated urgently within 2 weeks.
Patients with moderately to severe, active TED should be offered treatment within a
six weeks from presentation.
Multiple surgical treatments in patients requiring complex rehabilitative surgery,
should follow the sequence: orbital decompression/eye muscle surgery/lid surgery.
(5) Efficient Referral pathways from primary to secondary and tertiary care, should be well
defined and seamless.
(6) Equitable All patients should have access to excellent treatment.
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What this study adds
● This nationwide survey of ophthalmologists with an
interest in TED represents a valuable snapshot of
provisions of TED care in the UK, with findings
suggestive of scope for improvement.
● In this paper, we recommend a framework and
recommendations for more robust collaboration across
specialties and propose standards endorsed by multi-
disciplinary stakeholder societies.
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